Preparation, characterization and taste-masking properties of polyvinylacetal diethylaminoacetate microspheres containing trimebutine.
The objectives of this study were to produce acid soluble, polyvinylacetal diethylaminoacetate (AEA) microspheres containing trimebutine (as maleate), using a water-in-oil-in-water (w/o/w) emulsion solvent evaporation method, to characterize their in-vitro release properties, and to evaluate the taste-masking potential of this formulation in human volunteers. The pH of the external aqueous phase was the critical factor in achieving a high loading efficiency for trimebutine in the microencapsulation process; nearly 90% (w/w) loading efficiency was obtained at above pH 10. Trimebutine was completely released from AEA microspheres within 10 min in a dissolution test at pH 1.2, simulating conditions in the stomach, whereas at pH 6.8, the pH in the mouth, only small quantities of trimebutine were released in the initial 1-2 min. The results of a gustatory sensation test in healthy volunteers confirmed the taste-masking effects of the AEA microspheres. Finally, an attempt was made to encapsulate the salts of other basic drugs (lidocaine, imipramine, desipramine, amitriptyline, promethazine and chlorpheniramine) into AEA microspheres using the w/o/w emulsion evaporation method. The loading efficiencies were ranked in almost inverse proportion with the solubility of the drugs in the external aqueous phase. This study demonstrated the possibility of masking the taste of salts of basic drugs by microencapsulation with AEA using a w/o/w emulsion solvent evaporation method.
Hashimoto
Yoshimi
Y
Institute for Consumer Healthcare, Yamanouchi Pharmaceutical Co., Ltd, 17-1, Hasune 3-Chome, Itabashi-ku, Tokyo, 174-8612, Japan.
Tanaka
Masami
M
Kishimoto
Hideyuki
H
Shiozawa
Hiroyoshi
H
Hasegawa
Kazumasa
K
Matsuyama
Kenji
K
Uchida
Takahiro
T
D000465:Algorithms; D004339:Drug Compounding; D004655:Emulsions; D005079:Excipients; D005765:Gastrointestinal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008863:Microspheres; D011145:Polyvinyls; D012995:Solubility; D013649:Taste; D014287:Trimebutine / Q000008:administration & dosage* / Q000009:adverse effects
D004655:Emulsions; D005079:Excipients; D005765:Gastrointestinal Agents; D011145:Polyvinyls; C405622:polyvinylacetal diethylaminoacetate; D014287:Trimebutine